Last reviewed · How we verify

NCT03881566: PREICU

Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients

Completed Last updated 29 April 2021
What this trial tests

trial in Sepsis in 119 participants. Completed in 31 December 2020.

Timeline
1 March 2019
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorJongmin Lee
StatusCompleted
Study typeOBSERVATIONAL
Enrollment119
Start date1 March 2019
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across South Korea

Conditions studied

Sponsor

Jongmin Lee

Who can join

19 and older, any sex, with Sepsis or Immune Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03881566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing